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Abstract
Background: Bacillus Calmette-Guérin (BCG) vaccination may have nonspecific effects, i.e., effects on childhood
morbidity and mortality that go beyond its effect on the risk of childhood tuberculosis (TB). Though the available
scientific literature is mostly from observational studies, and is fraught with controversy, BCG vaccination at birth
may protect infants in high-mortality populations against serious infections other than TB. Yet, other studies
indicate that giving BCG later in infancy may modify immune responses to non-TB antigens and potentially
enhance immunity, potentially also against tuberculosis (TB). It is unclear whether BCG vaccination very early in life
offers adequate protection against TB and other infections among HIV-1-exposed children because even those who
remain uninfected with HIV-1 show signs of impaired immunocompetence early in infancy. This study will compare
BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV-1-exposed infants.
Methods: This is an individually randomized controlled trial in 2200 HIV-1-exposed infants. The intervention is BCG
vaccination within 24 h of birth while the comparator is BCG given at 14 weeks of age. The study co-primary
outcomes are severe illness in the first 14 weeks of life, and production of tumor necrosis factor, interleukin (IL)-1β,
IL-6 and interferon-γ in response to mycobacterial and nonmycobacterial antigens. The study is being conducted in
three health centers in Uganda.
Discussion: A well-timed BCG vaccination could have important nonspecific effects in HIV-1-exposed infants. This
trial could inform the development of appropriate timing of BCG vaccination for HIV-1-exposed infants.
Trial registration: ClinicalTrials.gov, identifier: NCT02606526. Registered on 12 November 2015.
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Background
BCG vaccination and nonspecific effects
Several observational studies suggest that routine child-
hood vaccines may have effects on childhood morbidity
and mortality that are separate from their effects on the
incidence of the diseases that they target [1–6]. Import-
antly, the Bacillus Calmette-Guérin (BCG) vaccine may
have effects on morbidity and mortality that cannot be
attributed to the vaccine’s protective effect against
tuberculosis (TB) [7–11]. A case control study among
infants in Guinea-Bissau showed that infants who had
received the BCG vaccine were at least 60% less likely to
have acute lower respiratory tract infections (ALRI) and
respiratory syncytial virus infections [12] than those who
had not been vaccinated. A small Malawian study indi-
cated that the likelihood of septicemia among infants
with a BCG scar was lower than that among infants
without a scar [13]. A Senegalese prospective study ana-
lyzing data from two birth cohorts (a total of 11,369
children under 2 years of age) found an association
between a combination of BCG/DTP administered
simultaneously and reduced mortality [1]. A secondary
analysis of data from a randomized controlled trial
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among low-birth-weight preterm infants indicated that
there may be an association between early BCG vaccin-
ation and lower perinatal mortality, but not lower infant
mortality [9]. In a birth cohort study in Uganda, we pre-
viously showed that children between 1 month and
5 years of age who had received BCG had a substantially
lower mortality than those who had not [14]. In fact, this
association was even stronger in the neonates but we
decided not to display this potentially important finding
because of the possibility that some of the association
could have been due to reverse causality, as vaccinators
could to some extent have refrained from giving BCG to
sick babies. Other observational studies among older
children, adolescents and adults have shown mixed
results for the effects of the BCG vaccine against atopy
[15–18] and helminthic infections [19–21]. Nonspecific
effects of vaccines, are now receiving increased atten-
tion, all the more so when the incidence of the TB is de-
creasing worldwide [22]. In fact, the World Health
Organization (WHO) recently established a Strategic
Advisory Group of Experts working group on NSEs of
vaccines [23].
Methodological challenges in existing studies
The medical literature on the NSEs of vaccines is
fraught with controversy [7]. Much of this controversy
stems from interpretational challenges of the observa-
tional studies carried out in high-mortality areas, and in
heavily burdened health care systems [24, 25]. It has
been argued that children with a lower morbidity and
mortality are more likely to be vaccinated than higher-
risk children, resulting in a spurious nonspecific protect-
ive effect of vaccines in observational studies [24, 25].
There is also the possibility of survival bias if death (a
common study outcome) is associated with missing
vaccination cards. This has been observed in some retro-
spective studies in Africa where child deaths were
quickly followed by destruction or loss of vaccination
cards [1, 24, 26, 27]. These selection challenges can be
alleviated by well-designed and well-executed random-
ized controlled trials. However, as most childhood
vaccines are part of routine national and international
child health programmes, it has been considered uneth-
ical to randomize children to not receive BCG. For this
reason, the medical literature on NSEs has continued to
be overshadowed by controversy and continues to be
dependent on initial studies carried out several decades
ago when morbidity and mortality patterns, as well as
the vaccines themselves, were different from what they
are now [24, 25]. Two recent systematic reviews con-
cluded that the currently available evidence, which is
mainly from observational studies, was of low quality
and reiterated the need for randomized controlled trials
[28, 29]. To the best of our knowledge, there are
currently no other, long-term, ongoing randomized trials
with clinical endpoints similar to ours.
Immunological reprogramming induced by BCG
In order to strengthen the medical literature, one of the
most important aims of the study is to identify any im-
munological reprogramming induced by BCG, which
has been recently suggested to be responsible for NSEs
[30]. The immunological responses thought to account
for the NSEs of BCG may, in broad terms, be considered
to involve two processes: trained innate immunity and
heterologous immunity. Trained immunity is a novel
concept that describes the functional reprogramming of
innate immune cells (such as monocytes, macrophages
or natural killer (NK) cells) after an infection or vaccin-
ation [31]. The molecular mechanism mediating trained
immunity is represented by epigenetic modifications due
to changes in histone methylation and acetylation, lead-
ing to a looser chromatin structure and increased gene
transcription [32]. Similar epigenetic reprogramming has
been described in monocytes of individuals vaccinated
with BCG [33]. In addition to trained immunity, a sec-
ond important immunological mechanism that is likely
to be involved in the NSEs is heterologous immunity:
the capacity of memory T-lymphocytes to respond in an
interleukin (IL)-12/IL-18-dependent manner with in-
creased production of cytokines upon stimulation with
different stimuli [34].
Timing of BCG vaccination among HIV-1-exposed children
Based on studies showing a nearly 1000-fold increased risk
of disseminated BCG infection among HIV-1-infected in-
fants, recent WHO guidelines consider HIV-1 infection a
contraindication to BCG vaccination [22, 35, 36]. How-
ever, the practical implementation of this guideline has
been difficult as HIV-1 diagnosis at birth (when the vac-
cine is to be given) is not available in many low- and
middle-income countries (LMICs) [35, 37]. As a result, all
HIV-1-exposed infants, including those yet to be diag-
nosed as HIV-1 infected, continue to receive BCG at birth
in several LMICs [35, 37]. To circumvent this, an alterna-
tive approach has been proposed in which the vaccine is
delayed until these infants are diagnosed as not having
HIV-1 infection [35, 37].
On the one hand, if vaccinating HIV-1-exposed babies
with BCG at birth protects them against serious infec-
tions other than TB, i.e., through NSEs [7, 8, 11], delay-
ing vaccination could result in increased morbidity and
even mortality. In addition, delaying BCG vaccination to
a later time when a definitive diagnosis is made could
reduce its coverage [37]. The Ugandan Ministry of
Health has decided that all infants, including those with
HIV-1 infection, but without symptomatic HIV-1
disease, are to receive BCG.
Nankabirwa et al. Trials  (2017) 18:152 Page 2 of 17
On the other hand, recent studies put into question
the age at which the BCG vaccine is best given to HIV-
1-exposed and uninfected children [35, 38–41]. It is
presently unclear whether BCG vaccination very early in
life provides them with adequate protection against TB
and other infections. HIV-1 infection during pregnancy
may transiently modulate their responses to the BCG
vaccine [38]. It appears that they have an impaired
response to purified protein derivative (PPD) and heat-
killed BCG in comparison to unexposed children [38].
These effects seem to be greatest among younger HIV-
1-exposed uninfected children. A recent study in Brazil
found the cellular immune response to BCG among
younger HIV-1-exposed uninfected children to be im-
paired in comparison to their unexposed counterparts
[35]. BCG-specific T-cell proliferation and interferon
(IFN)-γ concentrations were lower in the younger than
in the older HIV-1-exposed uninfected infants and than
in the unexposed infants. This signified a delay in im-
mune system maturation of HIV-1-exposed infants.
Moreover, a Gambian study showed that children vacci-
nated at a median age of 14 days were less likely to de-
velop a BCG scar if they were HIV-1-exposed uninfected
than if they were HIV-1-unexposed and uninfected [39].
A Rwandese study did not replicate this finding but
found that HIV-1-exposed uninfected children vacci-
nated at birth were substantially less likely than HIV-1-
unexposed children to react to a tuberculin skin test at
6 months of age [40]. Other studies have linked negative
tuberculin skin tests and absence of BCG scars to high
morbidity and mortality in children [41]. These BCG-
specific immune abnormalities are consistent with a
wider range of other anomalies reported among very
young HIV-1-exposed uninfected children and are
thought to result from in-utero exposure to the HIV-1
infection and/or antiretroviral drugs. These include: a re-
duced CD4/CD8 ratio, reduced CD4+ and CD8+ naive
T-cell percentages, an increased percentage of activated
CD8+ T-cells, augmented percentages of CD3(+)/4(−)/
8 (−) (DN) and DN/25(−)/44 (+) [42–44], altered cell-
mediated immunity and T-cell maturation [42], reduced
IL-12 production that persists until 6 months of age that
could possibly be immunosuppressive [45], and several
cytokine and other immune abnormalities [42, 43, 45–
47]. Importantly, many of these anomalies appear to be
transient, disappearing as children grow older.
A small trial in South Africa in which newborn
HIV-1-unexposed babies were randomized to receive
BCG at birth or at 10 weeks of age, showed that
delaying the vaccination resulted in increased num-
bers of BCG-specific CD4 T-cells, most importantly
polyfunctional T-cells co-expressing IFN-γ, tumor
necrosis factor (TNF)-α and IL-2, at 1 year of age
[48]. A recent study among HIV-1-exposed children
reported robust T-cellular responses to Bordetella per-
tussis and tetanus toxoid in infants in whom BCG
vaccination was delayed to 8 weeks of age [49]. It is
unknown, whether these effects of delayed BCG
administration translate into enhanced protection
against TB or, for that matter, against other serious
infections.
The most appropriate timing for BCG vaccination that
maximizes both specific and possible NSEs, particularly
in HIV-1-exposed children, is thus presently unknown.
This uncertainty compels us to study the NSEs of the
BCG vaccine with a design that overcomes the methodo-
logical challenges of observational studies.
Purpose and rationale of this study
A rapid increase in the number of HIV-1-positive preg-
nant women receiving antiretroviral treatment (ART) to
prevent mother-to-child transmission (MTCT) of HIV-1
in the last 10 years [50], coupled with stagnating or in-
creasing adult HIV-1 prevalence in LMICs, has resulted
in an increase in the number of HIV-1-exposed unin-
fected children [51–53]. While data on HIV-1-exposed
uninfected children is scanty, available evidence suggests
that these children have a higher morbidity and mortal-
ity in comparison to their unexposed counterparts [54,
55]. In comparison to unexposed children, HIV-1-
exposed uninfected children are more likely to contract
the common childhood infectious diseases in severe
forms [56–58], more likely to be hospitalized and more
likely to be resistant to treatment [59–62]. They are also
vulnerable to diseases previously reported among im-
munocompromised children, such as cytomegalovirus
colitis [63], hemorrhagic chicken pox, Pneumocystis jiro-
veci pneumonia and others [64].
Bearing the above considerations in mind, we believe
that there is clinical equipoise between early and de-
ferred BCG vaccination in HIV-1-exposed, and probably
even in HIV-1-unexposed infants. Moreover, the long-
term cost-implications and cost-effectiveness of the
alternatives have never been investigated.
It is possible that well-timed BCG vaccination could
have important NSEs in HIV-1-exposed children. We
therefore propose a parallel-group superiority trial that
could inform the development of programmatically ap-
propriate timing of BCG vaccination for HIV-1-exposed
infants by measuring the safety, potential benefits or dis-
advantages, costs and cost-effectiveness of early versus
late BCG.
Methods/design
Hypotheses
1. Compared to deferring BCG vaccination until
14 weeks of age, BCG administered within the first
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24 h of birth leads to at least a 30% relative risk
reduction of severe illness1 among HIV-1-exposed
infants
2. Delayed BCG results in at least a 30% higher
production of TNF, IL-1β, IL-6, IL-10, IL-17, IL-22
and IFN-γ in response to mycobacterial (from Myco-
bacterium tuberculosis and PPD) and non-
mycobacterial (from Escherichia coli, Candida albi-
cans and Staphylococcus aureus) antigens compared
to when BCG is administered at birth in HIV-1-
exposed infants
Primary objectives
To compare
1. The risk of severe illness in the first 14 weeks of life,
and
2. The production of TNF, IL-1β, IL-6, IL-10, IL-17,
IL-22 and IFN-γ in response to mycobacterial (from
M. tuberculosis and PPD) and non-mycobacterial
(from E. coli, C. albicans and S. aureus) antigens at
birth (before BCG vaccination) and at 1, 14, 15 and
28 weeks of age among HIV-1-exposed infants ad-
ministered BCG at birth with those administered a
delayed BCG
Secondary objectives
To compare:
1. The risk of severe illness from 48 h after
randomization until 14 weeks of life among HIV-1-
exposed infants administered BCG at birth with
those receiving delayed BCG
2. HIV-1-exposed infants who received BCG at birth
with those administered a delayed BCG with respect
to the occurrence of diarrhea, pneumonia and/or
severe illness from 14 weeks to 1 year of age
3. HIV-1-exposed infants who received BCG at birth
with those administered a delayed BCG with respect
to the occurrence of severe illness during infancy
4. Occurrence of diarrhea, pneumonia and/or severe
illness during infancy in HIV-1-exposed infants vac-
cinated with BCG at birth versus those who receive
delayed BCG
5. The mortality from birth to 14 weeks of age in HIV-
1-exposed infants vaccinated with BCG at birth ver-
sus in those who are yet to receive BCG
6. Infant mortality between HIV-1-exposed babies vac-
cinated with BCG at birth versus in those who re-
ceive delayed BCG
7. Through life-cycle modeling, long-term aggregate
health benefits and cost-implications of the delivery
strategies, and estimate their cost-effectiveness
To increase the diagnostic specificity, we will also try
to capture “clinical sepsis2,” where an infant with severe
illness and a negative blood culture, or from whom a
blood culture could not be taken, has two or more of
the following findings: total lymphocyte count (TLC)
<5000 cells/mm3, absolute neutrophil count <1,500
cells/mm3, band to total polymorph ratio >0.2 and both
of two C-reactive protein (CRP) levels >1 mg/dl in two
specimens taken 24 to 48 h apart. Because we are yet to
know in what proportion we can manage to collect the
required blood specimens, the comparison between the
risk of “clinical sepsis” and/or “confirmed sepsis3” be-
tween the two trial arms will form part of our secondary
analyses. Although it is unclear whether BCG scarring is
a marker of immune responsiveness in general and it
may be that such scarring is unrelated to protection
against TB, it is being captured as a marker of “vaccine
take.” We will also explore whether children with a scar
are less or more prone to severe illness during infancy.
The study will also examine the effect of the timing of
BCG administration on infant growth.
Intervention and co-interventions
The study intervention is an intradermal administration
to HIV-1-exposed babies of 0.05 ml Tubervac® BCG vac-
cine from the Serum Institute of India, the vaccine cur-
rently provided by the Ugandan vaccination programme.
After randomization within 24 h of birth, infants in one
trial arm will receive the vaccine immediately (BCG at
birth) while infants in the other arm will receive the
vaccine at 14 weeks of age (delayed BCG). Our study
nurses, already experts in administering all childhood
vaccines, including Tubervac®, will ensure that the
vaccine is administered as scheduled.
Key outcome measures
Primary outcome measures
1. Severe illness in the first 14 weeks of life
2. TNF, IL-1β, IL-6 and IFN-γ in response to mycobac-
terial (M. tuberculosis and PPD) and non-
mycobacterial pathogens (E. coli, C. albicans and S.
aureus) at 1, 14, 15 and 28 weeks of age
Secondary outcome measures
1. Severe illness from 48 h after randomization to
14 weeks of life
2. Severe illness and/or diarrhea and/or pneumonia
between 14 and 52 weeks and between 0 and
52 weeks of life
3. Adverse events up to 52 weeks of life
4. Infant death
5. Growth up to 52 weeks of life
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6. BCG scar 12 weeks post vaccination
Study setting
The study is being conducted in Kawaala Health Center
III, Kitebi Health Center III in Kampala district and in
Mukono Health Center IV, which is located in Mukono
district, 27 km east of Kampala. These centers were
chosen based on their proximity to laboratories essential
for specimen processing and their high number of HIV-
1-infected women attending their antenatal and birth
clinics. These three government facilities together con-
duct at least 1200 deliveries per month.
Selection of participants, inclusion and exclusion
criteria
HIV-1-infected pregnant women between 28 and
40 weeks of gestation attending antenatal care (ANC)
and receiving the national elimination of mother to child
(eMTCT) programme’s ART for life (Option B+) strategy
are approached by the study team (Fig. 1). ANC clinics
in the national programme offer routine opt-out HIV
counseling, testing and ART according to the national
guidelines and WHO’s Option B+ recommendation.
Pregnant HIV-1-infected women attending our three
study clinics are informed about the BCG study, its pur-
pose, benefits, risks and their potential eligibility. The
study team will encourage the women to deliver at the
health units and to follow the national guidelines in
order to mitigate MTCT of HIV during pregnancy,
childbirth and the breastfeeding period.
For the pregnant women, these guidelines include:
1. Daily, orally administered cotrimoxazole
2. Initiation of triple therapy (tenofovir, lamivudine and
efavirenz) starting during pregnancy and continuing
for life
3. Appropriately modified obstetric practices
4. Counselling and support for optimal infant feeding
For the HIV-1-exposed infants, these guidelines
include:
1. Nevirapine syrup for the first 6 weeks regardless of
infant feeding method
2. Daily cotrimoxazole starting at 6 weeks of age
For the HIV-1-infected infants, these guidelines
include:
1. Initiation of ART with zidovudine, lamivudine and
nevirapine or efavirenz as the preferred regimen.
2. Daily cotrimoxazole starting at 6 weeks
Inclusion criteria
A baby born at a participating study clinic is included if
they:
1. Have a mother with a positive HIV-1 test (ELISA or
rapid test)
2. Are receiving periexposure prophylaxis as part of
the standard/national Option B+ guidelines in
Uganda
3. Have a mother who is of legal age for participation
in clinical research studies in Uganda or is an
emancipated minor
4. Have a mother/caregiver who resides within the
study area, is not intending to move out of the area
in the next 4 months and is likely to be traceable for
up to 12 months
Fig. 1 Bacille Calmette-Guérin (BCG) trial participant screening,
enrollment and follow-up
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5. Have a mother/caregiver who gives informed
consent to trial participation
6. Have a mother who has received ART for at least
4 weeks
Exclusion criteria
A newborn child is excluded if they have:
1. Serious congenital malformation(s)
2. Severe illness requiring hospitalization
3. A birth weight <2.0 kg
4. A mother participating in another research study on
the day of enrollment or a mother who will
participate in another research study within the next
3 months
5. A mother or other household member with
symptoms and signs of TB on the day of enrollment
6. A severely ill mother with a condition or conditions
requiring hospitalization
Trial size estimates for the primary hypotheses
Hypothesis A
The outcome in this hypothesis is severe illness in the
first 14 weeks of life. Based on an estimated 10% risk of
severe illness in the first 14 weeks of life [65], 90% power
and a risk ratio of 0.7, the required sample size is 1914
(Table 1).
Taking into account 10% attrition and that up to 5% of
the infants may have contracted HIV-1 infection when
enrolled, a total of 2200 babies are required for this trial,
1100 children in each study arm.
Hypothesis B
The outcome for this hypothesis is the production of
relevant cytokines in response to mycobacterial and
non-mycobacterial antigens. Based on previous studies
[33, 66] we expect that comparisons involving 50 chil-
dren in each arm will be sufficient to detect biologically
relevant differences.
Randomization
Infants of HIV-1-infected mothers are randomized
within 24 h of birth using pre-prepared randomization
lists. Randomization is stratified by clinic using per-
muted blocks of varying size (4, 6 or 8). Eligible infants
are allocated in a 1:1 ratio to one of the two following
arms: BCG vaccination within 24 h of birth or BCG
vaccination at week 14. All computer-generated
randomization lists were prepared for each clinic by an
independent scientist, and are kept safely off site. Con-
cealment until the mother-infant pair has been deemed
eligible for final inclusion is ensured using an application
running on a dedicated Android cell phone at each
clinic.
Blinding/masking
Although scientifically advantageous, giving a placebo
injection in the delayed BCG arm may be practically and
ethically questionable, and the study is an open-label
trial. Rigorously trained [67] research assistants who rec-
ord outcomes are blinded as much as possible to which
trial arm the children belong. Further, the vaccine is ad-
ministered by routine health workers at the health cen-
ters that regularly administer the BCG vaccine as well as
other childhood vaccines.
Implementation plan, staff recruitment and
training
Field organization
Recruitment at each of the three health facilities is done
by three full-time research assistants (nurses) and a part-
time research assistant. The coordinator (ON) is respon-
sible for the day-to-day running of the study, and will
report to the principle investigator (PI; VN) and co-PI
(HS) who will ensure the overall scientific integrity of
the study. The study will also employ a data manager
that will oversee data quality. All study staff have
received intensive training on study procedures and
refresher training will be conducted during the trial.
Screening of pregnant women
All HIV-1-positive pregnant women between 28 and
40 weeks of gestation attending antenatal care at the
three clinics are informed about the study. Specifically,
they are informed that if they choose to participate in
the study, their infants will be randomized to receive the
BCG vaccine within 24 h of birth or at 14 weeks of age.
Consenting women are offered a CD4 cell count, a full
blood count including hemoglobin estimation and a clin-
ical assessment for HIV-1 disease staging and investiga-
tions for opportunistic infections, including TB.
Pregnant women who are eligible following the screen-
ing and who consent to participate are recruited into the
study at this first meeting. During recruitment, data on
Table 1 Assumptions used for sample size calculation for the
first 14 weeks of life
Assumption Estimated level
Two-sided significance level 0.05
Ratio of sample size early/late BCG vaccination 1
Percent of vaccinated at 14 weeks of age with
severe illness
15
Percent of vaccinated at birth with severe illness 10
Risk ratio: 0.7
Risk difference 5
Total sample size (i.e., in both trial arms) 1914
BCG Bacillus Calmette-Guérin
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baseline characteristics and other social-demographic
variables is collected.
Postnatal screening
Infants are assessed for other inclusion and exclusion
criteria, and if eligible, randomized into the study within
24 h of birth. At birth, blood is drawn to perform a de-
oxyribonucleic acid polymerase chain reaction (DNA-
PCR) assay for diagnosing any HIV-1 infection within
6 weeks of birth. The DNA-PCR assays are performed in
batches (on samples collected over a 1-month period;
Fig. 2) using standard procedures. In addition, cord
blood is collected for the child’s full blood count at base-
line. A sample of this cord blood is stored for future
investigations.
Collection of data on baseline features and
potential confounders
Data on relevant baseline characteristics is collected dur-
ing pregnancy and at birth. This will include indicators
of socio-demographic characteristics (maternal educa-
tion and age, food insecurity, income, employment, etc.),
health (illness history, parity, disclosure of HIV status to
a partner, clinical examination, hemoglobin, Body Mass
Index (BMI), viral load, CD4 cell count), premature rup-
ture of membranes, postpartum complications, adher-
ence to ART and cotrimoxazole prophylaxis, sex of the
child, infant feeding practices, and whether the mother
received tetanus toxoid during pregnancy as per national
recommendations.
Follow-up and subject retention
Follow-up visits at the study clinic are scheduled on day
7 and at weeks 2, 6, 10, 14, 15, 26, 28, 48 and 52 after
birth (Figs. 2 and 3). At each of these visits, data is col-
lected on the primary and secondary study outcomes,
adverse events (localized abscess formation, suppurative
lymphadenitis and disseminated BCG infection), anthro-
pometry and on potential confounding variables (see
above). Mothers are given a cell phone to facilitate con-
tact with study staff in case of an illness or other import-
ant child events.
Home visits will be made for participants missing
clinic visits while those coming to their scheduled clinic
visits will have the transport fees reimbursed to reduce
losses to follow-up. Data on illness, hospital visits and
hospitalization is collected from interviews with the
mother, with more detailed information obtained from
the hospital records. Illness and hospitalization data is
based on recall between a previous visit and a current
visit.
Upon enrollment and on subsequent visits, mothers
and other caregivers are informed about symptoms and
signs of severe illness, and are encouraged to contact the
study clinic in case the baby develops any of these symp-
toms. Each mother is provided with a durable note book,
Fig. 2 Time schedule for study procedures
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in which she is instructed and trained to note down all
relevant events in her child. The front page of the book
will have clear reminders that she needs to contact the
study team in case the child visits a health clinic, a
physician or is admitted to a hospital. A child who
comes to a clinic with such symptoms is examined by a
study nurse/midwife. If the child does not attend after
the mother/caregiver has informed the study team of
Fig. 3 Flow chart of study participants
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such signs or for a scheduled visit, the study nurse/mid-
wife will make a visit to the child’s house. If the nurse/
midwife classifies the condition as possible severe illness,
a study physician will be called to examine the child. If
the physician classifies the child as having severe illness,
they will collect a blood specimen for blood culture
(using BACTEC) and a sepsis screen (CRP, TLC, differ-
ential count, and band cell:neutrophil count ratio) as
soon as possible. A repeat specimen will be collected
again for CRP between 24 and 48 h. The study team will
do its utmost to obtain specimens for such a sepsis
screen from as many infants with signs of severe illness
as possible. However, we have yet to learn what percent-
age of them in this way can actually be screened for
“clinical sepsis.” When 200 enrolled babies have been
followed until the age of 6 months, the percentage of
infants registered as having had severe illness who are
screened for clinical sepsis will be calculated. If this
percentage is less than 80%, measures will be taken to
increase it above this value, if these measures are unsuc-
cessful, we will need to abandon the attempt to identify
clinical sepsis with the sepsis screen. Length and weight
measurements are taken twice at each visit, based on the
WHO guidelines, and z-scores calculated using WHO
child growth standards [68].
Data collection and management
All trial procedures have been standardized. Training ex-
ercises were undertaken and refresher sessions are
scheduled during the trial. Using Open Data Kit (ODK,
https://opendatakit.org), we will use pre-coded elec-
tronic Case Report Forms (eCRFs)/questionnaires with
range and consistency checks. Entered data will be
checked for consistency and any errors corrected
Source documents and files will not be destroyed with-
out specific written permission from the PI. Only the PI,
Co-PI, study coordinator and authorized study personnel
will have access to the CRFs and supporting documents
that will be kept on password-secured computers to en-
sure participant confidentiality. To ensure correct oper-
ation according to standard operating procedures (SOPs)
all system users have been trained in their use and evalu-
ated on a regular basis.
Clinical laboratory tests
Heel-prick blood samples are obtained from the children
for HIV-1 diagnosis. Dried blood spots (DBS) using a
commercial PCR kit are used for HIV-1 diagnosis. This
testing is supported by standardized protocols that have
been successfully validated in Uganda. Flow cytometry is
used for CD4 count measurement while standardized
automated procedures and techniques are used for
hematological and biochemical plasma assays. ELISA
and/or rapid tests are used for maternal HIV-1 diagnosis
according to the Ugandan national guidelines. At week
14 and week 52, blood will be drawn by venipuncture
for full/complete blood counts. TLC, differential count
and CRP will be captured as part of the sepsis screen in
babies with clinical severe illness.
Functional immunology assessment
We will investigate both the induction of trained im-
munity and heterologous immunity. Blood cells will be
stimulated for 48 h with a lysate of BCG or M. tubercu-
losis, and IFN-γ production will be measured by ELISA
as a measure of classical adaptive immunity. Using the
cell culture medium (RPMI) as a control stimulus,
trained innate immunity will be assessed by stimulation
of blood for 24 h by unrelated nonspecific stimuli: lipo-
polysaccharide (LPS), heat-killed E. coli, C. albicans or S.
aureus at 1, 15 and 28 weeks of age. Production of the
monocyte-derived cytokines TNF, IL-1β and IL-6 will be
assessed by ELISA. Genome-wide gene transcription will
be assessed in the unstimulated and stimulated whole
blood by ribonucleic acid (RNA) sequencing. Heterol-
ogous immunity will be assessed by measurement of
both Th1 (IFN-γ) and Th17 (IL-17, IL-22) cytokines in
blood stimulated for 96 h with the nonspecific stimuli
described above. The anti-inflammatory cytokine IL-10
will also be assessed at the 48-h stimulation time point.
Protein and messenger ribonucleic acid (mRNA) assess-
ment will be our main immunological readouts.
Quality assurance and quality control
We will use the WHO Good Laboratory Practice Guide-
lines [69] as our reference when establishing quality con-
trol laboratory procedures. HIV-1 serology, CD4 counts,
hematology/biochemistry and immunology assays are
submitted to a stringent quality assessment programme.
On-going training and monitoring will occur during the
study.
Handling losses, withdrawals and protocol
deviations
Protocol deviations
If a protocol violation, such as an inadequate informed
consent, inappropriate randomization or concealment or
wrongful enrollment of an under-age mother occurs, the
PI will inform the Independent Data Monitoring Com-
mittee (IDMC), which consists of a pediatrician, a statis-
tician and a pediatrician/immunologist), the Project
Management Team (PMT, which consists of some of the
authors of this paper) and the local Ethical Committee
as soon as possible and no later than five working days
after the event. Detailed documentation mentioning the
dates and reasons of these protocol deviations will be
kept by the PI. If continuing the child in the trial puts
the health of the mother or her child at risk, the child
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will no longer be followed up, but their data will be in-
cluded in time-to-event analyses up to the time that they
were removed from the trial.
Plan of analysis
The data will be analyzed using Stata version 14 or later
(StataCorp LP, TX, USA) and SAS version 9.2 or later.
Continuous variables with right-skewed distributions will
be log-transformed. Means with standard deviations will
be used to summarize symmetrically distributed con-
tinuous variables while medians with interquartile ranges
will be used for non-normally distributed continuous
variables, and percentages for categorical variables.
Between-group comparisons for continuous variables
that are symmetrically distributed will be made using t
tests or, if adjustment for other variables are required,
linear regression, while Wilcoxon rank sum tests will be
used to compare continuous variables where even their
log-transformed values remains nonsymmetrically dis-
tributed. Group comparisons for categorical variables
will use chi-square tests and regression with generalized
linear models of the binomial family with a log link
(“relative risk regression”) or logistic regression. We will
use two-sided statistical tests and 95% confidence inter-
vals for descriptive results, efficacy estimates and safety
estimates. All relevant data; from both scheduled and
unscheduled visits will be included in the analysis.
Primary analysis
The main study outcomes are severe illness during the
first 14 weeks of life and immunological parameters. Al-
though the sample size estimations are based on speci-
fied relative risks, i.e., the occurrence of one or more
illness episodes per child, our final analysis will also use
incidence density and use Poisson regression or, in case
of overdispersion, negative binomial regression analyses,
to estimate incidence rate ratios (IRR), enabling us to
capture more than one illness event in each child. Fur-
ther, children who are lost to follow-up will be included
in time-to-event analyses, censoring children during
periods when data could not be recorded. All random-
ized children will be included in an intention-to-treat
analysis.
To take into account multiple study events occurring
in the same child, we will in the regression models
utilize generalized estimating equations (GEE), as appro-
priate. The effect of the intervention on the occurrence
of severe illness will be estimated using both relative
(relative risks (RR), IRR and hazard ratios (HR)) and ab-
solute (risk differences and incidence rate differences
(IRD)) measures of effect. In the event that the “relative
risk regression” model fails to converge, risk ratios will
be obtained from logistic regression [70] or from a
modified Poisson regression model with robust variance
[71, 72].
Also, autoregressive correlation approaches will be
used to account for multiple and possibly correlated ob-
servations within the same study participant. These
methods take the correlation structures into account
and thereby the fact that measurements taken closer in
time for an individual are likely to be more correlated
than two measurements taken farther apart for that
same individual. Efficacy will be calculated as 100 × (1 −
RR), 100 × (1 − IRR) or 100 × (1 −HR). The prevalence of
BCG scarring will be compared between the two study
arms using the abovementioned approaches, as appro-
priate. Linear regression and or t tests will be used to
compare the TNF and IFN-γ responses between the trial
arms. We will consider adjusting for potential con-
founders if: (1) there are baseline imbalances between
trial arms, (2) the variables for which there are such
baseline differences are strongly associated with the
study event or (3) they cause a ≥5% difference in the ef-
fect measures when they are added to the main model.
Full case analyses will be default, but appropriate impu-
tations will be considered for missing data.
In addition to the intention-to-treat analysis, where
outcomes will be compared according to the random al-
location, instrumental variable analyses will be con-
ducted in an attempt to estimate biological/causal effects
of the actual receipt of the vaccine. In these analyses,
random allocation will be the instrument. To enable
such analyses, actual receipt as well as the age of BCG
vaccination will be captured in all participants. We will
also perform per-protocol and as-treated analyses.
The primary analyses will include all HIV-1-exposed
infants, adjusting for any imbalance in HIV-1 status be-
tween the two trial arms, as appropriate. However, we
will also perform an analysis of the large subgroup of ba-
bies who remain uninfected with HIV-1.
Secondary analysis
1. Risk of severe illness from 48 h after randomization
until the first 14 weeks of life, after the 14 weeks of
infancy and during the entire infancy period will be
analyzed as described above for the primary analysis
2. As a hypothesis-generating effort to understand the
latency period after which BCG may induce NSEs,
we will calculate the protection against severe illness
during the first 14 weeks of life on a sliding scale
starting from randomization until seven completed
days post randomization
3. Risk of child death in the first 14 weeks as well as in
the remaining 38 weeks of infancy: time-to-event
analysis will be used to estimate time to severe ill-
ness or death. Kaplan-Meier methods and log-rank
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tests will be used for descriptive analyses. The results
from these analyses will be presented as Kaplan-
Meier probabilities of the endpoints by a specified
time for every 1000 children. Cox proportional haz-
ards regression models will be used to estimate the
effect of the intervention on child death. For this
outcome, data will be censored when a child is lost
to follow-up
4. Risk of clinical sepsis and of “confirmed sepsis” in
the first 14 as well as in the remaining 38 weeks of
infancy
5. Safety will be analyzed according to type, frequency
and severity of adverse events (AEs) that occur in
children during the trial
6. Subgroup analysis for potential effect measure
modification will be on the strata defined by
maternal CD4 counts (<350 or ≥350 cells/μL), low
birth weight (<2500 or ≥2500 g) and the babies’ HIV
status, sex of the child, in addition to other baseline
characteristics which we have reasons to believe may
interact with delayed BCG administration. Such
subgroup/interaction analyses will be defined based
on the available scientific literature before
embarking on the analyses, will not be driven by
study data, and will be described in a detailed
analysis plan
7. Survival analyses using nonparametric and
parametric methods to extrapolate over 5 years the
incidence of NSEs and death for use in economic
evaluation
Plan of analysis for economic evaluation
A Markov life-cycle decision model will be developed to
model long-term aggregate health and cost implications
of the delivery strategies, and to compare their cost-
effectiveness. The decision model will have two arms,
one for early, the other for delayed BCG administration
(Fig. 4). A Markov life-cycle will be attached to each de-
livery arm, in which infants are followed in weekly cycles
from 0 to 14 weeks, monthly cycles between 14 and
52 weeks, and thereafter yearly cycles. The model will
track one annual Ugandan cohort of HIV-1-exposed in-
fants until they are 5 years old.
The main focus of the model will be severe illness dur-
ing the first year of life, and will rely on prospectively
collected trial data (Table 2). For each cycle (weekly,
monthly or annual) children may experience disease, or
they may remain healthy. Children aged below 1 year are
assumed to be at risk of experiencing a disease other
than TB which may persist or from which they recover
before the next period. In all health states, individuals
may die from that illness or from other causes. At birth,
all children are assumed to be alive and well.
The model represents a simplification of clinical real-
ity, and a simplifying assumption is that BCG-induced
protection against severe illnesses occurs only during
the first 5 years of life. This reflects the availability of
primary data and follow-up from the controlled trial.
Modeling of the health outcomes may be divided into
three phases: (a) the observation period, (b) the period
of assumed but gradually waning impact of the vaccine
(less than 5 years) and (c) the post-vaccine period, where
no further vaccination effects are assumed. Extrapolation
is required to capture probable health benefits during
the second of these phases, but the actual functional
shape and other assumptions about continued treatment
benefits need to be informed by data through survival
analyses, and cannot be decided ex-ante. Transition
Fig. 4 The decision model
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probabilities are assumed to depend on vaccination
strategy, and will be informed by the trial. More specific-
ally, transition probabilities, i.e., probabilities of moving
between the health states, will be calculated based on
hazard functions from the survival analyses (above).
After the extrapolation period, children are not assumed
to be protected by BCG, but are assumed to experience
background mortality and morbidity for their remaining
life time. Long-term health effects will be aggregated
using disability-adjusted life years (DALYs) as the instru-
ment, while incremental cost-effectiveness will be
expressed in terms of US dollars per DALY averted.
Costs will be collected from the perspective of the na-
tional health care system, and include those related to
providing the BCG vaccine as well as those averted due
to the prevention of common illnesses in the short and
long term.
AE reporting/clinical and safety monitoring
An adverse event (AE) is defined as any harmful mani-
festation occurring in a trial participant, whether this
manifestation is related or not to the study BCG vaccine.
Potential AEs include localized abscess formation at the
injection site, suppurative lymphadenitis and dissemi-
nated BCG infection.
AE monitoring, recording and reporting
Potential AEs will be carefully monitored throughout the
trial with specific questionnaires. The mothers will be
invited and encouraged to consult the study clinic in
case of any disease or symptoms that arise between
visits. AEs will be investigated at each follow-up visit.
Each AE will be reported spontaneously or in response
to general, nondirected discussion with the attending
midwife/researcher or physician/researcher. All AEs,
regardless of seriousness, severity, or presumed relation-
ship to study therapy, will be recorded using medical ter-
minology in the source document and on the AE page.
Whenever possible, diagnoses will be given when signs
and symptoms are due to a common aetiology. Investi-
gators will record their opinion concerning the relation-
ship of the AE to BCG vaccination on the AE page. AE
reporting
When the investigator, or trained physician, becomes
aware that a serious AE (SAE) has occurred, the appro-
priate reporting form will be completed, and a copy
emailed to the local Institutional Review Board.
Management of SAEs
In case of an SAE, the mother will be encouraged to im-
mediately use the dedicated cell phone to contact the re-
search unit and or to bring the infant immediately to the
research unit. Infants will be seen by one of the research
midwives/clinicians and appropriate medical or surgical
interventions will be provided. All SAEs will be followed
up until resolution or until a stable clinical endpoint is
reached. Insurance coverage is by BiomedicInsure
(http://www.biomedic-insure.com), and if any participant
is harmed as a result of the BCG vaccine (within 2 years
of the vaccination) they will be compensated
Monitoring
Independent Data Monitoring Committee (IDMC)
A group of independent scientists with expertise in
pediatrics, immunology, TB and statistics forms an
IDMC. After meeting shortly before trial start, it will
periodically review and assess available study data for
safety, conduct and efficacy. The board will advise the
project management on study continuation, modification
or termination based on its reviews and pre-established
stopping rules.
Interim analysis: an interim analysis for safety taking
into account the DAMOCLES group recommendations
[73, 74] will be performed by the IDMC when approxi-
mately half of all the expected events have been
recorded.
Auditing
The study will be monitored once a year by scientists
not involved in the day-to-day undertaking of the trial.
Protocol amendments
Important protocol modifications (such as those result-
ing from changes to eligibility criteria, outcomes and
planned analyses) will be communicated to, and dis-
cussed among, the PMT members, discussed with the
IDMC and, when appropriate, the Ethics Committees.
Such modifications will also be reflected in amendments
to the description in ClinicalTrials.gov (NCT02606526).
Table 2 Economic evaluation data requirements and sources
Parameter Source
Epidemiology
Age-specific disease incidence Primary data (for each condition)
Background mortality Secondary data (Ugandan life table)
Effectiveness
Disease-specific efficacy Primary data
Uptake of intervention Secondary data: effective coverage
of vaccination
Aggregate health
Years of life lost Secondary data (Ugandan life table)
Disease weights Secondary data (Burden of Disease
Study)
Costs
Intervention costs Primary data (prospectively costed)
Treatment costs Primary data (retrospectively costed)
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Dissemination of study findings
Our study findings will be communicated in scientific
conferences and published in peer-reviewed scientific
journals. We will also prepare contextualized evidence
briefs for policy to relevant stakeholders including Ugan-
dan authorities (Ministry of Health, National Drug Au-
thority, Uganda National Academy of Sciences) and
development partners supporting the Uganda National
Expanded Programme on Immunization (UNEPI), WHO
(Vaccines and Biologicals) and UNICEF. We will, also in
collaboration with CISMAC, prepare plain language
summaries and press releases for consumer groups and
mass media, respectively. Finally, we will engage the
clinic staff and study participants and their communities
to inform them of our findings.
Ethical considerations
According to WHO guidelines, BCG vaccination is con-
traindicated in children with known HIV-1 infection [22,
35, 36] because of their increased risk of disseminated
BCG disease. But implementation of this guideline in
many LMICs, including Uganda, is challenging. Accord-
ing to the expanded programme of immunization, the
vaccine is to be given as soon as possible after birth.
Diagnosing HIV-1 infection in infants requires a PCR
which is not accessible to Ugandan children at birth.
Therefore, Ugandan HIV-1-exposed newborns receive
BCG at birth. On the one hand, receiving the vaccine at
birth could be of potential benefit through morbidity
and mortality reduction in the initial weeks of life. On
the other hand, recent medical literature indicates that
HIV-1-exposed uninfected infants [35, 38–41], and
maybe even HIV-1-unexposed infants [48], who receive
BCG somewhat later may yield more vigorous immune
responses than those who receive it at birth. It is con-
ceivable that such a delay translates into better protec-
tion against TB. Delaying vaccination may also carry the
advantage of increasing the likelihood that HIV-1-
exposed infants may be reliably diagnosed with respect
to HIV-1 infection, both for logistic reasons but also be-
cause there is a genuine risk of HIV-1 transmission via
breast milk during the first months of life [75]. This trial
will compare BCG take and risk of severe illness (includ-
ing death) among HIV-1-exposed children receiving the
vaccine shortly after birth to such a risk in infants re-
ceiving BCG at 14 weeks of age.
The main ethical concerns specific to study are:
1. Acquisition of TB before BCG has engendered a
protective immune response (delayed BCG trial
arm)
2. Severe BCG disease among HIV-1-positive infants
(early BCG trial arm)
3. Higher incidence of severe illness during the first
14 weeks of life among the children who receive
delayed BCG
To address the first concern, the study will exclude
children with household members who have signs or
symptoms of TB or who have a diagnosis of TB. The risk
of TB infection among trial babies will, therefore, be
negligible [76]. In addition, the study will continue to ac-
tively screen and refer suspected cases to the national
TB clinics until the participating infants have received
BCG (at 14 weeks of age). The study will support diag-
nosis and initiation of treatment at the TB clinics, of any
of the participants’ household members with signs and
symptoms of TB from randomization until 14 weeks of
age. Moreover, the study team will collaborate closely
with the families to identify, treat and actively follow up
the babies should there be a history of exposure to active
TB or should they develop any symptoms indicative of
TB. Should our study show that delayed vaccination is
beneficial in terms of protecting HIV-1-exposed babies
against severe illness and in the long run it leads to a
policy shift, with HIV-1-exposed children from house-
holds without TB being vaccinated late, our findings will
inform subsequent programmes and would thereby con-
tribute to improved infant health.
To mitigate the second concern, an HIV-1 diagnosis
using DNA PCR is obtained at 6 weeks of age. All children
who are allocated to receive BCG at birth and are found to
be infected with HIV-1 will be referred to a pediatrician for
assessment, while the HIV-1-infected participants allocated
to receive BCG later will be referred to government clinics
for a decision to vaccinate or not. In a sample of 1100 chil-
dren, the probability of disseminated BCG is extremely low.
This is because in the presence of the current Ugandan
peripartum ART prophylaxis the risk of HIV-1 infection
assessed at 6 weeks of age is less than 3.5% [77]. Therefore,
among the 1100 babies who receive BCG at birth, fewer
than 40 children are likely to acquire HIV-1. Among chil-
dren with immunodeficiency, it is estimated that the risk of
disseminated BCG infection following vaccination is less
than 1.6 per 1,000,000 vaccinated children [78]. Therefore,
the likelihood of any child contracting disseminated BCG
in our study is less than 0.015% if the government clinics
decide to vaccinate all the HIV-1-infected infants at 14 years
of age, and 0.007% if they decide not to vaccinate any of
them. So, this risk will be equal to, or lower than, that out-
side of the study, given that Ugandan HIV-1-exposed in-
fants receive BCG shortly after birth. In the study, we shall
reduce this risk further with prompt standard TB prophy-
laxis using isoniazid as soon as an HIV diagnosis is made.
With regard to the third concern, appropriate diagnos-
tic procedures and treatment will be provided according
to national guidelines to all severely ill children.
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Ethics permission to conduct the study has been ob-
tained from the School of Medicine, Research and Ethics
Committee (Makerere University) as well as from the
Regional Committees for Medical and Health Research
Ethics in Norway (REK) [79]. The trial has also been ap-
proved by the National Council of Science and Technol-
ogy and the National Drug Authority in Uganda. The
study is performed in accordance with International
Conference on Harmonization (ICH) guidelines for
Good Clinical Practice. Written individual informed
consent in local language is obtained from each of the
participating mothers by trained study staff. The consent
process will explain the nature of the study, the risks
and benefits of participating in the study, the interven-
tion and that intervention allocation is by a random
process. In situations requiring translation or in cases
where the mother is unable to read and write, the con-
sent process will take place in the presence of an inde-
pendent third person, who will act as a witness and also
co-sign the Consent Form. Additional consent is ob-
tained from study participants for the collection and
storage of blood specimens for ancillary studies. Confi-
dentiality of information and the right of the participant
to withdraw from the study at any time during the study
is explained to the mothers. All study staff are trained
on participant confidentiality and autonomy.
Discussion
This trial compares the effect BCG vaccination at birth
with BCG vaccination at 14 weeks of age in HIV-1-
exposed babies on (1) severe illness in the first 14 weeks
of life, (2) TNF, IL-1β, IL-6, IL-17, IL-22 and IFN-γ in
response to mycobacterial and non-mycobacterial patho-
gens and (3) severe illness in 14–52 weeks of life and
throughout infancy.
The study circumvents the methodological challenges
of earlier observational studies that reported an associ-
ation between BCG vaccination and NSEs. The exclu-
sion criteria combined with the random allocation and
large sample size will substantially reduce the likelihood
that children with higher morbidity end up in either
group. There will be no survival bias linked to missing
vaccination cards as BCG is administered before out-
come measurement. This study will be further strength-
ened by an exploration of immunological mechanisms
for the vaccine’s hypothesized NSEs. The study will ex-
plore the trained innate immunity and heterologous im-
munity processes that underlie the immunological
responses thought to account for the NSEs of BCG.
This trial, comparing NSEs when the vaccine is given
at birth and when it is delayed, could inform the devel-
opment of programmatically appropriate timing of BCG
vaccination for HIV-1-exposed infants. This, in turn
could importantly impact morbidity and mortality
among these infants, who will constitute an increasing
part of sub-Saharan African child cohorts in the years to
come.
Trial status
Recruiting since July 2016.
Endnotes
1Among children aged below 2 months of age, severe
illness (other than TB) will be defined as illness that is
associated with any of the following danger signs ob-
served or verified by a study clinician: inability to feed
or vomiting of everything, lethargy or unconsciousness,
severe lower chest in-drawing, axillary temperature of
≥37.5 °C or <35.5 °C, grunting, cyanosis, convulsions or
a history of convulsions, and/or results in hospitalization
and/or results in death.Among children aged 2 months
of age or older, severe illness (other than TB) will be de-
fined as illness that: is associated with at least one of the
following danger signs observed or verified by a study
clinician: inability to drink or breastfeed, lethargy or un-
consciousness, vomiting of all feeds, convulsions or a
history of convulsions, and/or results in hospitalization
and/or results in death. Hospitalization and death result-
ing from violent injury or burns will not contribute to
the severe illness definition.
2In infants from whom a blood culture was not per-
formed or in whom a blood culture was negative, clinical
sepsis is signaled by one of our study physicians (VN,
ON, JKT or GN) having initiated treatment for sepsis or
confirmed that such treatment was appropriate and/or
by a positive sepsis screen. A positive sepsis screen is the
presence of any two of the following: total leukocyte
count <5000/mm3; absolute neutrophil count <1500/
mm3; band cell:neutrophil count ratio >0.2; both of two
C-reactive protein serum levels in specimens taken 24 h
to 48 h apart >1 mg/dl.
3Confirmed sepsis is signaled by a blood culture that is
positive for bacteria known to cause infant sepsis.
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